Aprea Therapeutics
APRE
28 hedge funds and large institutions have $8.48M invested in Aprea Therapeutics in 2024 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
17% more funds holding
Funds holding: 24 → 28 (+4)
5.08% less ownership
Funds ownership: 43.46% → 38.38% (-5.1%)
21% less capital invested
Capital invested by funds: $10.8M → $8.48M (-$2.29M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
+$707K |
| 2 |
EAM
Exome Asset Management
New York
|
+$707K |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$707K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$79.7K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$57.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.08K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
-$1.03K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$722 |
| 4 |
PGAM
Princeton Global Asset Management
Princeton,
New Jersey
|
-$669 |
| 5 |
OPTFSNA
Old Point Trust & Financial Services N A
Newport News,
Virginia
|
-$335 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
JP Morgan Chase
New York
| $49 | +$62 | +12 | New |
|
|
AF
27
Aviso Financial
Toronto,
Ontario, Canada
| $41 | +$52 | +10 | New |
|
28
UBS Group
Zurich,
Switzerland
| $12 | – | – | – |
|
|
29
Fidelity Investments
Boston,
Massachusetts
| – | -$1.08K | -161 | Closed |
|
|
PGAM
30
Princeton Global Asset Management
Princeton,
New Jersey
| – | -$669 | -100 | Closed |
|
|
OPTFSNA
31
Old Point Trust & Financial Services N A
Newport News,
Virginia
| – | -$335 | -50 | Closed |
|
APRE Hedge Fund Activity: Q2 2024 in Review
28 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Aprea Therapeutics (APRE) for Q2 2024, worth a combined $8.48M — down 21% from $10.8M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new APRE positions and 3 closed out — a net gain of 4 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Altium Capital Management, opening a new position worth an estimated $707K. The largest seller was Fidelity Investments, exiting entirely with an estimated $1.08K sold.
- 28 institutional investors held Aprea Therapeutics (APRE) as of Q2 2024, up from 24 in Q1 2024.
- Funds reported $8.48M of Aprea Therapeutics stock for Q2 2024, down 21% quarter-over-quarter.
- 7 funds opened new Aprea Therapeutics positions in Q2 2024 and 3 closed out, a net change of +4 holders.
- The largest Aprea Therapeutics buyer in Q2 2024 was Altium Capital Management, an estimated $707K added.
- The largest Aprea Therapeutics seller in Q2 2024 was Fidelity Investments, an estimated $1.08K sold.
Based on aggregated 13F filings for Q2 2024.